Testing vicadrostat plus empagliflozin for heart failure
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether adding a new study drug called vicadrostat to the standard heart failure medicine empagliflozin helps people with heart failure. It may be a good option if you have heart failure with preserved pumping function and are not already on a medicine called an MRA.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have had chronic heart failure for at least 3 months.
- Your heart's pumping strength (ejection fraction) is 40% or higher.
- You have a structural heart abnormality (like an enlarged heart or thickened heart muscle).
- You have a high level of NT-proBNP (a protein that goes up when heart failure is worse) in your blood.
- You are not taking an MRA (like spironolactone) or certain other potassium-sparing medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called vicadrostat combined with another drug, empagliflozin, for people with heart failure and a weak heart pump. It aims to see if this combination helps improve symptoms and outcomes.
This study tests if a new medicine (vicadrostat) works differently than an older one (spironolactone) in people with heart failure or heart disease and reduced kidney function. It aims to understand how they affect proteins in the blood and kidney blood flow.
This study tests whether a new drug called baxdrostat, when added to the diabetes medicine dapagliflozin (Farxiga), can prevent heart failure and heart-related death in people with type 2 diabetes, high blood pressure, and existing heart or blood vessel disease. You may be able to join if you have type 2 diabetes, heart or blood vessel disease, high blood pressure, and at least one extra risk factor for heart failure.
This study tests an experimental medicine called NNC0537-1482 for people with heart failure. It aims to see if the medicine helps improve symptoms and heart function.
This trial tests whether adding dapagliflozin (a medication that helps protect the heart and kidneys) helps people with heart failure who are also on peritoneal dialysis. It may offer extra support for your heart and kidney health.
This study tests a new pill called vicadrostat taken with another medicine (empagliflozin) to see if it helps people with type 2 diabetes, high blood pressure, and heart disease. It may reduce the risk of heart problems, but you must not have had heart failure or use certain other heart medications.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.